BRPI0409475A - inibição de vav na rejeição de enxerto - Google Patents

inibição de vav na rejeição de enxerto

Info

Publication number
BRPI0409475A
BRPI0409475A BRPI0409475-1A BRPI0409475A BRPI0409475A BR PI0409475 A BRPI0409475 A BR PI0409475A BR PI0409475 A BRPI0409475 A BR PI0409475A BR PI0409475 A BRPI0409475 A BR PI0409475A
Authority
BR
Brazil
Prior art keywords
vav
graft rejection
inhibition
inhibitors
xenograft
Prior art date
Application number
BRPI0409475-1A
Other languages
English (en)
Inventor
Michael Forstner
Martin Klumpp
Lukas Leder
Barbara Nuesslein-Hildesheim
Friedrich Raulf
Gisbert Weckbecker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308853A external-priority patent/GB0308853D0/en
Priority claimed from GB0315090A external-priority patent/GB0315090D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0409475A publication Critical patent/BRPI0409475A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"INIBIçãO DE VAV NA REJEIçãO DE ENXERTO". A presente invenção refere-se a um método para a prevenção ou tratamento de rejeição a enxerto aguda ou crónica em um recebedor de alo- ou xenotransplante de célula, tecido ou órgão, doenças inflamatórias ou auto-imunes ou doença proliferativa maligna, compreendendo o uso de um inibidor de Vav. Ainda são fornecidos inibidores de Vav, usos, composições farmacêuticas e combinações terapêuticas compreendendo inibidores de Vav, e métodos de triagem para os mesmos.
BRPI0409475-1A 2003-04-16 2004-04-15 inibição de vav na rejeição de enxerto BRPI0409475A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0308853A GB0308853D0 (en) 2003-04-16 2003-04-16 Organic compounds
GB0315090A GB0315090D0 (en) 2003-06-27 2003-06-27 Organic compounds
PCT/EP2004/003982 WO2004091654A1 (en) 2003-04-16 2004-04-15 Vav inhibition in graft rejection

Publications (1)

Publication Number Publication Date
BRPI0409475A true BRPI0409475A (pt) 2006-05-02

Family

ID=33301222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409475-1A BRPI0409475A (pt) 2003-04-16 2004-04-15 inibição de vav na rejeição de enxerto

Country Status (8)

Country Link
US (1) US20070042948A1 (pt)
EP (1) EP1617868A1 (pt)
JP (1) JP2006525248A (pt)
AU (1) AU2004229171B2 (pt)
BR (1) BRPI0409475A (pt)
CA (1) CA2522104A1 (pt)
MX (1) MXPA05011075A (pt)
WO (1) WO2004091654A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017161A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
WO2005056024A1 (en) * 2003-12-05 2005-06-23 Children's Hospital Medical Center Methods of enhancing stem cell engraftment
FI121073B (fi) * 2008-10-15 2010-06-30 Suomen Punainen Risti Veripalv Menetelmä solujen suojaamiseksi
US8980861B2 (en) 2010-10-26 2015-03-17 President And Fellows Of Harvard College Method for determining activators of excitatory synapse formation
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN115372611B (zh) * 2022-07-18 2023-05-30 中山大学孙逸仙纪念医院 Cd16+成纤维细胞在诊断、预防和治疗单克隆抗体耐药乳腺癌中的应用
WO2026013578A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Combinations comprising vav1-targeting degraders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348864A (en) * 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5612212A (en) * 1993-11-12 1997-03-18 The University Of Pennsylvania Selective inhibition of cell proliferation by vav antisense oligonucleotides
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US6323317B1 (en) * 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
US5776698A (en) * 1997-04-14 1998-07-07 Incyte Pharmaceuticals, Inc. Regulation of gene transcription
US20020068271A1 (en) * 1999-12-27 2002-06-06 Amnon Altman Methods for identifying agents capable of modulating protein kinase C theta (PKC0) activity

Also Published As

Publication number Publication date
AU2004229171B2 (en) 2007-10-25
CA2522104A1 (en) 2004-10-28
EP1617868A1 (en) 2006-01-25
WO2004091654A1 (en) 2004-10-28
MXPA05011075A (es) 2006-04-18
AU2004229171A1 (en) 2004-10-28
US20070042948A1 (en) 2007-02-22
JP2006525248A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ECSP104578A (es) Derivados de indolilmaleimida como inhibidores de proteína de cinasa c
EP1576110A4 (en) CELL HANGING COMPOSITIONS AND METHOD AND COMPOSITIONS FOR CANCER TREATMENT
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
EP1691759A4 (en) PROTEIN EXTRACT COMPOSITIONS AND PROCEDURES DERIVED FROM PLANTS
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
ATE448232T1 (de) Substituierte heterozyklen
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
CY1110559T1 (el) Συνδυασμοι που περιλαμβανουν εποθιλονες και αναστολεις πρωτεϊνικων τυροσινικων κινασων και φαρμακευτικες χρησεις αυτων
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.